mRNA Platform

Global Market Trajectory & Analytics

MCP23108

EXECUTIVE ENGAGEMENTS

POOL

796
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

168
Interactions with Platform & by Email

PARTICIPANTS

41
Unique # Participated

VALIDATIONS

18
Responses Validated*

COMPANIES

96
Responses Validated*
* Login for a full stack data experience

DATE

AUG 2021

TABLES

34

PAGES

334

EDITION

2

PRICE

USD 5600

CODE

MCP23108


COMPETITIVE METRICS

COMPANY

D S N T

% *

Accanis Biotech F&E GmbH & Co KG

Accent Therapeutics

Acuitas Therapeutics

ADARx Pharmaceuticals, Inc.

AKESOgen, Inc.

Aldevron

Altogen Labs

AmpTec GmbH

Anima Biotech, Inc.

Arcturus Therapeutics, Inc.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

The ongoing Covid-19 pandemic has highlighted the potential for mRNA therapies. The mRNA technology has experienced decades of research efforts from scientists and various biotechnology companies. Discovered in the 1960s as an option to convert DNA codes into proteins, mRNA took several decades to emerge as promising therapeutic modality for various medical conditions. mRNA medicines make use of the usual biological processes to extract proteins and create the required therapeutic effect, due to which the treatment of several diseases that cannot be achieved using current technologies is made easy. mRNA therapeutics have gained major attention following the development of new synthesis as well as delivery approaches. The advances in the generation, purification and cellular delivery of RNA have widened the scope of RNA-based therapeutics for a broad array of applications. The technology is marked by its compelling advantages over traditional methods in terms of turnaround times, production speed and cost savings. Various clinical and preclinical studies have indicated promising results for protein replacement therapies, prevention of infectious diseases, tumor immunotherapy and cancer vaccines. In the historic global race to develop a vaccine, mRNA based Covid-19 vaccine from Moderna and Pfizer stand out as frontrunners. The unique characteristics of mRNA has made it of great interest to vaccine developers. While traditional vaccines have used live or inactivated pathogens to elicit an immune response, mRNA is responsible for cellular processes, building structures, regulating functions, and building structural components. mRNA vaccines work by introducing a part of mRNA that reacts to the viral protein. It accelerates production of antibodies and trains the immune system to recognize the virus in the future, thereby offering protection. Essentially a chemical process, production of mRNA vaccines eliminates the need for growing proteins or viruses, a key reason why vaccines by Moderna and Pfizer/BioNTech quickly reached human trials. For instance, Moderna`s vaccine was created in just six weeks. Securing approval for emergency use, the two vaccines demonstrated around 95% efficacy in eliciting immune response against the COVID-19 virus during clinical trials.

Beyond Covid-19, mRNA-based therapies hold promise for combatting cancer, infectious diseases such as malaria and flu, and rare genetic diseases. Results from early animal testing demonstrates the ability of mRNA-based therapeutics to provide protection against viruses such as influenza, Zika and rabies. With the effectiveness of mRNA vaccines against Covid-19, there is heightened research interest in pursuing mRNA platform for treating infectious diseases, for example, BioNTech is preparing to launch the first vaccine for malaria based on mRNA technology with plans to conduct clinical testing by the end of 2022. Similarly, Moderna also announced plans to conduct human trials for an HIV vaccine. Currently, of the total 44 ongoing clinical trials of mRNA vaccines, 23 of them are aimed at infectious diseases. Cancer research has used mRNA platform to trigger the immune system to target specific cancer cells. Currently, there are many clinical trials underway utilizing mRNA vaccines for various cancers. Most of the mRNA cancer vaccine trials are targeting tumors such as melanoma and kidney cancer. An mRNA vaccine could be custom-made to match the genetic signature of an individual`s cancer. This personalized mRNA vaccine could be used following surgery to program the immune system to search out and destroy any residual cancer cells, and thus prevent the cancer from recurring. For instance, the pipelines of Moderna and BioNTech include drug trials for treating cancers of the brain, breast, prostate, pancreas, lung, skin and other tissues. The mRNA vaccines market is projected to receive notable contribution from the cancer segment that is estimated to claim the leading revenue share over the coming years. The segment`s growth is augmented by increasing incidence of cancer. The condition remains one of the major causes of mortalities globally, with the number of new cases annually exceeding 23.6 million by the year 2030.

mRNA is also being pursued to aid in rapid development of drugs for rare diseases. Recent advancements in the structural composition of mRNA have led the scientific community to swiftly embrace it as a new drug to deliver missing genes to organs. The pipelines of Moderna, CureVac and BioNTech, three major biopharmaceutical companies, cover heart diseases, metabolic diseases and immunomodulators for applications in immuno-oncology. The introduction of synthetic mRNA into human cells opens scope for a replacement therapeutic option for conditions known for defective or inadequate synthesis of key proteins. The approach holds significant potential over protein replacement and gene therapies owing to its lower risk, affordability and less frequent dosage. mRNA can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins. Many mRNA-based protein replacement therapies are under development for the heart, lungs and liver. For example, Cardior Pharmaceuticals, a Germany-based biotechnology company, is working on RNA drugs for treatment of heart failure. Translate Bio developed a protein replacement therapy for cystic fibrosis, which is currently undergoing Phase 1/2 clinical trial. In addition, mRNA is being explored as potential alternative to the gene therapy for treatment of intractable medical conditions like sickle cell disease. Increased scientific interest and funding brought on by the pandemic is expected to further boost advancements in mRNA vaccine and therapeutics technologies. The widespread recognition is leading to new uses of mRNA being developed and approved.

SELECT PLAYERS

BioNTech AG; CureVac AG; Dicerna Pharmaceuticals; eTheRNA Immunotherapies; ethris GmbH; In-Cell-Art; Moderna, Inc.; Regulus Therapeutics; Sangamo Therapeutics, Inc.; Tiba Biotech; Translate Bio, Inc.

SEGMENTS

» Indication (COVID-19 Vaccine, Cancer Vaccine, Other Indications)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
The Race Between the Virus & Vaccines Intensifies
Effectiveness of Vaccinations
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Saving Lives with Vaccines
Dosing Interval Adjustment to Expand Coverage
Global COVID-19 Vaccine Inequity
Accessibility of Vaccines
Impact of Vaccine Inequity on the Economy
Impact of Vaccine Inequity on the Labor Market
Financing Vaccines
MRNA - A CONCEPTUAL UNDERSTANDING
MRNA: A New Approach to Medicine
Long Wait & Scientific Breakthroughs
mRNA Vaccines - An Introduction
With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development
mRNA: Making Cells Act as Vaccine Factory
mRNA Vaccines: Advantages
mRNA Vaccines: Cons
mRNA Vaccine Approvals
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Traditional Vs. mRNA Vaccines: Key Differences
Traditional Vs. mRNA Vaccines: The Development Process
How mRNA Vaccine Works & Earlier Testing Efforts
mRNA Vaccines: Safety Quotient
Other Notable Efforts Centered on mRNA Technology
Overcoming Challenges
As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community
GLOBAL MARKET OVERVIEW
Global mRNA Vaccines Market on a Dynamic Growth Track
Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead
COVID-19 mRNA Vaccine Approval Details
COVID-19 Funding Details of Moderna and Pfizer Vaccine
EXHIBIT: Production Capacity of mRNA Frontrunners in Millions of Doses for 2021
COVID-19 Pandemic: An Eventful Year for RNA
COVID-19’s Impact on Vaccine Development – A Transformative Shift to mRNA vaccines
mRNA Based Vaccines in Clinical Development
EXHIBIT 7: Vaccines in Pipeline by Technology
EXHIBIT 14: Vaccine Technologies in Pre-Clinical Studies
VARIOUS VIRUS VARIANTS
COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge
Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse
Investigating the Virulence Profile of India’s N440K Variant
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
Rising Cases in South Africa & Other Countries
California Strain Emerges to be More Contagious and Deadly
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study
mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market
The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations
RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE
Pfizer and BioNTech’s COVID-19 Vaccine Receives World’s First Authorization
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine
After UK, US Gives Nod to Pfizer’s Vaccine
EU Approves Pfizer’s Vaccine
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna’s mRNA Vaccine Bags Approval from US FDA
Moderna Kick-Starts Inoculation in the US
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Recent Market Activity
COMPETITIVE SCENARIO
BioNTech – A Pioneer in mRNA-based Vaccines and Therapies
List of BioNTech’s mRNA Candidates in Clinical Trials for Cancer
Moderna’s Ambitious Stride into Vaccine Development: From a Novice to Know All
Moderna’s mRNA Prophylactic Vaccines
mRNA Cancer Vaccines
mRNA Intratumoral Immuno-Oncology
mRNA Systemic Secreted & Cell Surface Therapeutics
mRNA Systemic Intracellular Therapeutics
Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19
mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon
Noteworthy Startups Exploiting mRNA Technology
The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Coronavirus Cases Drive the Market Demand
Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead
mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum
EXHIBIT 8: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
EXHIBIT 10: Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018
EXHIBIT 11: Number of AIDS-Related Deaths (in Thousands) by Region for 2018
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Increasing Healthcare Expenditure to Foster Market Growth
EXHIBIT 2: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
EXHIBIT 5: Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Regulatory Landscape for mRNA Vaccines
Regulatory Pathway Dealing with mRNA Vaccines
mRNA Vaccine Patent Scenario
The Best Route of Administration for mRNA Vaccines
CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021)
mRNA CANCER VACCINES
Introduction
Cancer Vaccines Vs. Immunotherapies
EXHIBIT: Clinical Trials of mRNA Encoding Immunostimulants
mRNA Vaccines Vs. DNA Vaccines
EXHIBIT: Clinical Trials of mRNA Encoding TAAs
mRNA Vaccines Vs. Other Vaccines
EXHIBIT: Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag)
mRNA Benefits Profile
mRNA Vaccines for Covid-19 Pave the Way
Challenges
Personalized mRNA Vaccine
Clinical Overview of mRNA Cancer Vaccines
mRNA encoding Immunostimulants
mRNA vaccine encoding tumor-associated antigens
mRNA vaccine encoding Neoantigen, personalized vaccine
mRNA Influenza Vaccines
Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform
Vaccines Built on mRNA
Clinical Trials for mRNA Vaccines
mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts
mRNA: A Next-Generation Vaccination Approach
Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses
COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots
mRNA Vaccines Vs. Other Flu Shots
mRNA Technology, H/N Spike Proteins & Clinical Trials
mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines
Benefits & Limitations of mRNA Vaccines over Traditional Options
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
World 6-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2022 & 2027
World Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
World 6-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027
World Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
World 6-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027
World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027
UNITED STATES
US FDA Gives Nod to Pfizer and Moderna’s mRNA Vaccines
Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government
Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland
US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15
Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply
USA Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
USA 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
CANADA
Vaccination Gathers Steam Across Canada
EXHIBIT 21: Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021
COVID-19 Vaccine Deals in Canada
Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021
Canada Grants Approval to Pfizer’s COVID-19 Shot for Use in Children in 12-15 Years Age Group
Canada Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Canada 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
JAPAN
COVID-19 Vaccination Programs in Japan Move Forward at Snail’s Pace
Reasons Responsible for Setback
Vaccine Timeline & Availability
Japan Demands for Vaccine-Related Data
People’s Low Trust in Vaccines
Japan’s Efforts to Develop Indigenous Vaccines
Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population
Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine
Japan Pushes Shipments of Pfizer’s COVID-19 Shots to Vaccinate Elderly
Japan Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Japan 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
CHINA
BioNTech’s Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China
China Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
China 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
EUROPE
EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021)
COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch
EU Approves Pfizer’s Vaccine
EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU
Europe Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
Europe 6-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2022 & 2027
Europe Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Europe 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
FRANCE
France Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
France 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
GERMANY
Germany Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Germany 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
ITALY
Italy Plans to Produce mRNA Vaccines Domestically
Italy Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Italy 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
UNITED KINGDOM
Market Analysis
UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine
Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine
UK’s Independent Vaccine Deals
UK Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
UK 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Rest of Europe 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
ASIA-PACIFIC
INDIA
Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India
AUSTRALIA
Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca
NEW ZEALAND
New Zealand Acquires Ultra-Cold Freezers to Store Pfizer’s COVID-19 Vaccine
Asia-Pacific Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Asia-Pacific 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
REST OF WORLD
THE MIDDLE EAST
BAHRAIN
Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer’s Vaccine
AFRICA
SOUTH AFRICA
New Virus Variant in South Africa Creates a Challenge
Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa
LATIN AMERICA
Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries
BRAZIL
Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech
MEXICO
Mexico’s Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine
Rest of World Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
Rest of World 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027
Total Companies Profiled: 96

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com